Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
The All-Weather Portfolio: The Good, The Bad, And The Ugly
06:06pm, Wednesday, 06'th Apr 2022 Seeking Alpha
The Financial Prophet's All-Weather Portfolio AWP delivered another solid quarter in Q1. Read the latest updates for the all-weather portfolio here.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
09:50pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
In the latest trading session, Gilead Sciences (GILD) closed at $59.75, marking a -1.52% move from the previous day.
Gilead: Buy For Dividend, HIV And Cancer Therapies
04:20pm, Tuesday, 05'th Apr 2022
Gilead is a leader in anti-viral therapies.
Roche (RHHBY) Actemra Application Receives Priority Review
04:06pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
12:58pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Top Analysts Say 8 Q1 Underperforming Dividend Stocks Could Be Huge Q2 Winners
07:15am, Tuesday, 05'th Apr 2022
After the first down quarter since 2020, many across Wall Street are examining the winners and losers for the quarter and shuffling the deck, looking for stocks that have the best upside potential for
Where Gilead Sciences Stands With Analysts
04:01pm, Monday, 04'th Apr 2022 Benzinga
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
6
1
0
Last
10 Biggest Price Target Changes For Monday
12:09pm, Monday, 04'th Apr 2022 Benzinga
Keybanc raised the price target on Block, Inc. (NYSE: SQ) from $175 to $180. Block shares rose 2.8% to $137.42 in pre-market trading.
SVB Leerink cut Calithera Biosciences, Inc. (NASDAQ: CALA) pri
2 Drugmakers Set for Explosive Revenue This Decade
10:00am, Sunday, 03'rd Apr 2022 The Motley Fool
They are selling much-needed products.
Best Options YTD - Quarterly Review
10:03am, Friday, 01'st Apr 2022
Best Options YTD - Quarterly Review
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
03:23pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
12:47pm, Thursday, 31'st Mar 2022
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
12:14pm, Thursday, 31'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Amylyx Says FDA Committee Casts Negative Vote On ALS Drug
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
09:50pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $59.66, moving -1.44% from the previous trading session.
5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy
02:15pm, Wednesday, 30'th Mar 2022 The Motley Fool
The company gives investors plenty of reasons to buy and hold the stock for years.
